Compare MCI & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCI | ELDN |
|---|---|---|
| Founded | 1971 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 364.9M | 300.3M |
| IPO Year | N/A | 2014 |
| Metric | MCI | ELDN |
|---|---|---|
| Price | $17.72 | $3.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 35.0K | ★ 1.3M |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 8.46% | N/A |
| EPS Growth | N/A | ★ 30.67 |
| EPS | ★ 1.82 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.57 | $1.35 |
| 52 Week High | $23.00 | $4.60 |
| Indicator | MCI | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 52.18 | 55.41 |
| Support Level | $17.27 | $3.35 |
| Resistance Level | $18.08 | $4.09 |
| Average True Range (ATR) | 0.37 | 0.32 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 70.00 | 44.60 |
Barings Corporate Investors is a closed-end management investment company. Its investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. The Trust's principal investments are privately placed, below-investment grade, long-term debt obligations, including bank loans and mezzanine debt instruments. The Trust typically purchases these investments, which are not publicly tradable, directly from their issuers in private placement transactions, and the investments are typically made to small or middle market companies.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.